Shijiazhuang Yiling Pharmaceutical (002603) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was RMB 2.36 billion, down 6.52% year-over-year, while net profit attributable to shareholders rose 7.25% to RMB 325.95 million.

• Net profit excluding non-recurring items increased 11.23% year-over-year, indicating improved core profitability.

• Operating cash flow surged 190.67% year-over-year to RMB 340.10 million, reflecting strong cash generation.

Financial highlights

• Gross margin improved as net profit grew despite a decline in revenue.

• Basic and diluted EPS both increased 7.26% year-over-year to RMB 0.1951.

• Total assets at quarter-end were RMB 13.69 billion, up 2.81% from year-end 2024.

• Shareholders' equity rose 3.19% to RMB 10.55 billion.

Key financial ratios and metrics

• Weighted average ROE was 3.14%, up 0.52 percentage points year-over-year.

• Operating margin improved as operating profit reached RMB 398.57 million.

• Cash flow from operations to net income ratio increased significantly.